Long-term disease-free survival (DFS) has been reported after autologous stem cell transplantation for acute lymphoblastic leukemia. Phase II studies have evaluated its role in first and subsequent complete remission (CR) with DFS rates of up to 50%. It has been under-utilized in 1st CR in part, due to a concern that patients who relapse after autologous stem cell transplantation (ASCT) have fewer options for salvage treatment of relapsed disease. Unfortunately, survival rates of o5% are reported in patients who relapse, regardless of initial therapy. Few prospective, randomized trials have analyzed large enough numbers of patients to allow us to determine the appropriate patient population for autologous transplantation. Although variability in the available studies makes it difficult to draw a definite conclusion, and many issues remain unresolved, available data suggests that there may be a group of patients for whom ASCT in first remission is a reasonable and perhaps superior treatment choice. Factors such as risk features at diagnosis, and minimal residual disease following induction therapy greatly affect outcome following ASCT. The available data as well as the questions that remain to be answered will be discussed and reviewed. Although acute lymphoblastic leukemia (ALL) is the most common cause of leukemia in children, in whom 90% are cured of the disease, up to 20% of the cases of ALL occur in adults. Despite improved induction response rates of up to 90%, relapse rates and therefore mortality remain high. Aggressive induction followed by more potent intensification or chemotherapy and stem cell transplant (SCT) may improve outcome. Although allogeneic SCT seems best for all adults under age 55 years with ALL, this option is often not available due to the lack of an human leukocyte antigen (HLA) identical sibling donor.
1 As in AML, it is thought that in patients with relapsed disease, the best chance at long-term disease-free survival (DFS) is with some form of transplantation. Autologous BMT for ALL was first introduced as a treatment for ALL nearly 50 years ago.
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At that time it was offered only to patients with relapsed and/or refractory disease. Despite the potentially terminal nature of their disease, long-term DFS has been accomplished in some patients. More recently, autologous stem cell transplant (ASCT) has been evaluated in patients in first remission, with leukemia-free survival at 5 years reported to be from 45 to 65% in published studies.
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Few prospective, randomized trials have analyzed large enough numbers of patients to allow us to determine the appropriate therapy for all patients with ALL. Based on the studies that are currently available, the general consensus regarding treatment of ALL in adults is as follows: [13] [14] [15] [16] (1) Allogeneic transplant from an HLA identical sibling is the treatment of choice in non-elderly adult patients with ALL in first remission. (2) Autologous transplantation should be considered in patients with 'highrisk' disease who do not have an HLA identical sibling and has a role in patients with relapsed disease. (3) Patients who relapse after ASCT have fewer options for treatment of relapsed disease. (4) Post transplantation maintenance is not useful.
The data that are currently available and will be reviewed suggest otherwise. (1) With improved techniques to evaluate minimal residual disease (MRD), it may be possible to identify patients who have a decreased risk of disease relapse. There may actually be a group of patients for whom ASCT in first remission is a reasonable and perhaps superior treatment choice. (2) The standard rather than the high-risk patients may be the ones who are most likely to benefit from autologous transplantation in first remission. (3) The outcome of patients who relapse after initial remission is dismal, regardless of whether or not they have had an autologous transplant in first remission. The use of ASCT in first remission does not adversely affect the outcome at the time of relapse. (4) Unlike AML, as will be discussed below, late relapses are not uncommon. 20 For patients in second remission, DFS and OS were 21 and 24%, respectively, with a 75% relapse rate. 20 
Data from nonrandomized trials

Preparative regimen and purging
Preparative regimens used for autologous transplantation have been evaluated primarily in studies of patients undergoing allogeneic transplant. No randomized trials have compared preparative regimens in the autologous setting. There is no clear benefit to any preparative regimen. 17, 20 An ongoing retrospective analysis of the CIBMTR database is evaluating the importance of total body irradiation (TBI) dose as well as chemotherapeutic agents in allogeneic transplantation in ALL. A TBI dose of 41300 Gy does appear to be superior with respect to risk of relapse (D Marks, personal communication, manuscript in preparation).
Efforts have been made to purge the bone marrow or stem cells of patients who are proceeding to autologous transplant. Although many studies have used various ex vivo purging techniques in ALL, no randomized studies have evaluated the role of purging in ALL. In vitro purging has been extensively studied in ALL, due to the welldefined antigens that characterize this disease and the availability of monoclonal antibodies against these antigens. These antibodies have been used alone or in combination with immunotoxins or magnetic beads. 21, 22 As in AML, 4-HC has also been used as a purging agent. Although in vitro laboratory studies have demonstrated reduction in tumor cells, clinical studies, mainly in the form of retrospective analyses have not demonstrated any survival benefit to purging. Although there may be a lower relapse rate in patients who received purged autografts, the potential benefit is offset by a higher transplant-related mortality. 17 Furthermore, several studies have evaluated the effect of purging on leukemic progenitor cells. Although ex vivo purging can decrease the number of leukemic progenitor cells in the autologous graft, there is no correlation between purging efficacy or the dose of residual tumor infused and the outcome.
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Minimal residual disease
There does appear to be a correlation between MRD at the time of stem cell collection and outcome from transplant. Multiple pediatric trials have demonstrated the prognostic significance of MRD in patients after completion of standard chemotherapy. [25] [26] [27] Reports are now available on small numbers of patients who have been transplanted with no evidence of MRD. In one report, four patients had marrow that was purged and MRD-negative post-purge. 28 Three of four patients are in continuous complete remission (CR) 26-77 months post-autologous transplant. 28 In ASCT, higher levels of MRD before stem cell collection have been associated with higher risks of relapse post transplant. 5, 22, 23, 29 This has been true in patients with Philadelphia chromosome positive (Ph þ ) disease as well. In the Leucemies Aigues Lymphoblastiques de l'Adulte (LALA) 94 trial, although the molecular status of the patient at the time of transplant had no impact on the outcome following an allograft, in patients who underwent autologous transplant the molecular status of the graft was critical. 13 In those patients who had persistent bcr-abl positivity at the time of stem cell collection, the OS was 12% as compared to 56% for those patients who had no detectable bcr-abl transcript at the time of collection. 13 A recent report from the ECOG 2993/MRC UKALLXII study has shown, in small numbers of patient samples, that for patients with pre-B cell ALL, the presence of MRD-positive disease following induction therapy is predictive of relapse. 30 This is an area that requires further investigation, particularly as molecular techniques are now allowing us to assess for MRD in the majority of patients with ALL. 
Philadelphia chromosome positive disease
The presence of the Philadelphia chromosome is a negative prognostic factor with a poorer induction remission rate, and a higher relapse rate after any form of post-remission therapy. 31 Allogeneic transplant is considered to be the best form of post-remission therapy in these patients. 20, 31 Although a wealth of literature exists regarding the significance of MRD in chronic myeloid leukemia, little data exist on MRD in Ph þ ALL. Now that imatinib is available for patients with Ph þ disease, the interest in autografting for ALL may increase as this agent can be used as an in vivo purging agent as well as post-autograft maintenance therapy. The German Multicenter ALL cooperative have already shown that molecular response at the time of stem cell harvest are noted when imatinib is incorporated into the induction regimen. 32 
Phase III trials
Several randomized trials have been published, which lend some insight into the treatment of ALL. The definition of high-risk disease differs between trials. The designs of the trials and the results are highlighted below.
The French LALA Group has performed several large prospective trials in ALL. In LALA 87, following remission induction, patients over age 50 years received consolidation chemotherapy, central nervous system (CNS) prophylaxis and maintenance chemotherapy. 33 Patients under age 40 years who had an HLA identical sibling underwent allogeneic transplant. Those between ages 40 years and 50 years and those under age 40 years without an HLA-typed family donor were to be randomized during the second of three scheduled courses of consolidation to continue with conventional chemotherapy or to proceed to autologous BMT following the third cycle of consolidation, using cells collected after the second cycle, and purged with mafosfamide. Patients were considered to be high risk if they had any of the following features: Philadelphia chromosome positivity, null or undifferentiated leukemia, age over 35 years, leukocyte count above 30 000/ml, time to CR 44 weeks. With a median follow-up of 10 years, OS of 572 evaluable patients was 27%. 33 The results are outlined in Table 2 . Based on an intention-to-treat analysis, survival following allogeneic transplant was superior to chemotherapy for patients with high-risk disease (44 vs 11%, P ¼ 0.009). The study was not designed to compare allogeneic to autologous transplantation; however in a retrospective analysis there was no difference between the two treatment options in standard risk disease. Although there was no clear difference between treatments, there was a trend for better results in autologous SCT when compared to chemotherapy for the standard risk group as well as the group as a whole (OS of 34% for autologous transplant vs 29% in the chemotherapy arm).
In the subsequent LALA-94 trial, they adopted a riskadapted post-remission strategy in adult ALL. 13 After an intensified induction therapy, four groups were defined based on initial clinical and biologic characteristics, and by their response to initial therapy: standard risk group (Group 1), a high-risk group (Group 2), a Ph þ group (Group 3) and a CNS-positive group (Group 4). Patients who were PhÀ, without evidence of CNS involvement who did not meet the criteria for standard risk on the basis of white blood cell count, cytogenetics and response to induction therapy, were considered to be high risk. Treatment options were determined by the risk group. Patients in group 1 were randomized to standard vs intensive chemotherapy. Patients in groups 2, 3 and 4 were offered an allogeneic transplant if an HLA identical sibling was available. For the others in group 2, patients were randomized to chemotherapy vs autologous transplant. Patients in group 3 and 4 were taken to autologous transplant if a sibling transplant was not performed. A total of 171 patients were treated on this study. Allogeneic transplant was superior to ASCT in groups 2 and 4. Table 3 highlights the survival and relapse rates seen with autologous transplant and chemotherapy in the various arms. Although there was no clear benefit seen to ASCT, the group that had a trend toward a possible benefit in their earlier trial, the standard risk group, was not offered that form of therapy in this trial.
The ongoing ECOG/MRC study will hopefully allow us to address this question in standard risk patients as well. 34 In this trial, all patients who do not have an HLA identical sibling (or an unrelated donor if Ph þ ) are randomized to autologous transplant vs standard chemotherapy. Over 1200 patients have been enrolled to date. In preliminary analysis, although there is a statistically significant benefit to allogeneic transplant in all subgroups, the results of the randomization have not yet been released, and the study continues to increase the number of patients being randomized. 35, 36 Given that the data safety and monitoring board has allowed the study to continue, one would suspect that there is no obvious superiority to one arm over the other, for the group as a whole, on preliminary short-term analysis.
Late relapses and the role of post transplant maintenance therapy
Although few randomized trials have been performed, several other interesting findings can be gleaned from various trials that have been reported. The Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study compared allogeneic transplantation following induction and compared it to ASCT following an additional intensification. 16 One of the interesting findings in this study was that, with follow-up ranging from 1.9 to 75 months, the last allogeneic transplant relapse occurred at 31 months, whereas there was not a plateau in the relapse rate at 6 years for ASCT. Similarly, The Royal Marsden Group has published its results of 77 patients with ALL who underwent autologous transplant in first complete remission. In an update, which has a median follow-up of 10 years, they report that a plateau was not reached in the DFS curve until 7-8 years following transplant. 18 Late relapses, occurring after 3 years, are unfortunately not uncommon in ALL. Reports indicate that a plateau, with respect to relapse incidence, following standard therapy or ASCT is often not reached for 6-7 years. 13, 16, 17, 19 Given the incidence of late relapses seen following ASCT, the role of post transplant maintenance has been questioned. In the GOELAMS trial, patients randomization to alpha interferon following autologous transplant did not have any effect on relapse or survival. 16 In the Royal Marsden study, maintenance therapy with 6MP and Methotrexate was planned for all patients following autologous transplant for 2 years. 18 In the initial years of the study, those who were not able to maintain adequate absolute neutrophil counts were given vincristine and prednisone instead of the other agents. After 1995, vincristine and prednisone were added to the maintenance regimen for all patients. A recent update on 65 patients who have undergone autologous transplant has been reported. 37 Twelve patients received no maintenance chemotherapy at all because of transplant-related mortality, relapse or patient choice. Among patients alive and well at 120 days, those getting two or three maintenance chemotherapy agents had a significantly lower relapse rate (15/41 vs 6/10), higher DFS and OS (P ¼ 0.0008). This benefit was greatest in patients with no adverse risk factors (age over 30 years, poor risk cytogenetics, 44 weeks to remission). In the only 14 patients with two or more adverse risk factors, there was no benefit to having received 2-3 agents (Table 4) . 37 In the LALA-94 trial, based on preliminary data from the Royal Marsden group, all patients who underwent ASCT were to receive 6MP and MTX as maintenance therapy. 13 Although they note that many of these patients did not receive the planned maintenance, it is of interest that in this trial, there were no relapses seen in the autologous transplant arm beyond 3 years. Although there data are not randomized, it does suggest that there may be a role for post transplantation maintenance therapy.
Outcome following relapse
There appears to be some hesitation in the community to perform autologous transplants in first remission ALL because of a theoretical negative impact on salvage therapy in the event of relapse. The Royal Marsden study was actually initially designed to also allow the evaluation of the outcome of allografting in second remission for patients relapsing after autologous transplant. 18 Although in the initial cohort of patients, only those without sibling donors Table 4 Maintenance therapy following ASCT: outcome for various risk groups who received 0-3 maintenance agents 38 At a median follow-up of 10 years, however, 30 patients (39%) had relapsed 1.5-80 months (median 12.5 months) following transplant. Eighteen patients died of relapsed disease or toxicity of salvage chemotherapy. Ten patients underwent allogeneic transplant from either a sibling or MUD donor. Of those 10 patients, nine died of transplant-related toxicity, two died with relapsed disease and two were alive and well in second CR at 7 and 1.5 years. 18 A retrospective analysis by the EBMT of patients who received autografts for acute leukemia in remission between 1981 and 1996 evaluated the outcome of those who relapsed as well. Patients with both AML and ALL were included in this analysis. Although the vast majority of patients received chemotherapy only, there were cohorts that underwent second transplants. The median 2 year survival was 11% in the group that only received chemotherapy. However, in those who underwent second transplant, the 2 year probability of survival was 3777% (95% CI) if the transplant was from an HLA identical donor and 59710% (95% CI) in those who underwent second autograft using cells collected in second CR. 39 The reason that most patients did not receive a transplant is not available. However, there is some suggestion that second transplants can be performed and can result in long-term DFS.
How these patients would have fared had they relapsed following chemotherapy is also not available from the above analyses. The poor overall outcome may be related to the disease biology rather than the history of an autologous transplant in first remission. In a retrospective analysis of 314 patients with primary refractory or relapsed ALL from MD Anderson, of whom 89% did not receive a SCT in first remission, 31% of patients achieved a CR with salvage therapy and only 11% of those who achieved a CR proceeded to transplantation. 40 Median overall CR duration was 6 months with a median OS of 5 months. At 1 year, 24% of patients were alive with a projected 5-year survival of 3%. In the ongoing ECOG 2993/MRC trial, a report is available on 359 patients under age 50 years who relapsed who had not had a prior autologous transplant in first remission. 41 In this group of patients, 101 were able to receive a subsequent transplant. Nine of these 101 patients are alive at 5 years from relapse and two of the patients who did not undergo a transplant are alive at 5 years for a 3% 5 year OS after relapse. Once relapsed, the prognosis is dismal.
Conclusion
Although limited data are available from randomized trials, there is reason to re-evaluate our paradigm for the use of autologous transplant in ALL. Many questions and issues remain unanswered (Figure 1 ). Patients should be entered on clinical trials whenever possible. Based on the data that are currently available we would propose that (1) Autologous stem cell transplant is a viable treatment option for patients with ALL in first and subsequent remission. (2) For patients with ALL, the ideal autologous transplant candidate might be the standard risk patient in first remission who does not have any evidence of MRD before stem cell harvest. (3) There may be a role for autologous transplant in the Ph þ patient, particularly in the era of imatinib. (4) There may be a role for long-term maintenance therapy in patients who undergo autologous transplantation in first remission. (5) Although some have voiced a concern that the use of autologous transplant in first remission may limit the options of patients if and when they relapse, there are no data to suggest that an autologous transplant in first remission has any effect on the outcome from salvage therapy. In general, once patients relapse, the outcome is poor. Therefore, the use of therapies that decrease the risk of relapse in first remission is essential. The benefits of ASCT will be maximal at that time. 
